CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 614 enrolled
Drug / intervention
Fluvastatin XL®drug
Likely dose
Fluvastatin XL® 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00664742
NCT00664742Phase 4Completed
CompareCT.gov

The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome

Novartis·interventional·Posted Apr 23, 2008·Updated May 17, 2011

In Brief

A Phase 4 clinical trial evaluating Fluvastatin XL® for Metabolic Syndrome. Completed, enrolled 614 participants across 1 site.

Detailed Summary

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesTurkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 23, 2008
Enrollment StartSep 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.2 years ago

Interventions

Fluvastatin XL®drug

Fluvastatin extended release 80 mg